This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state’s Prescription Drug Price Transparency Program was created to illuminate pharmaceutical pricing practices, but pharmaceutical companies have shielded information they say infringes on trade secrets.
Rep. Rob Nosse, D-Portland, touted his aggressive and innovative approach to tackling uncontrolled pharmaceutical costs on Thursday, calling on Oregon to lead where Congress has failed and other state-based reforms have fallen short.